TEE
ITCI

Tibra Equities Europe’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Tibra Equities Europe’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-43,300
Closed -$527K – 455
2019
Q1 		$527K Buy
+43,300
New +$553K 0.05% 257

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Tibra Equities Europe's ITCI Position: Q2 2019 in Review

Tibra Equities Europe sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2019, closing a stake of 43,300 shares — an estimated $527K sold.

Tibra Equities Europe first reported a position in ITCI in Q1 2019 and held it in 1 quarter. The position peaked at $527K in Q1 2019. 126 funds tracked by Wall St. Rank hold ITCI as of Q2 2019.

  • Tibra Equities Europe reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 43,300 Intra-Cellular Therapies Inc. shares in Q2 2019, an estimated $527K.
  • Tibra Equities Europe first reported a position in Intra-Cellular Therapies Inc. in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Intra-Cellular Therapies Inc. position peaked at $527K in Q1 2019.
  • 126 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.